Neuroprotective Potential of Diosmetin and Polmacoxib against Scopolamine-Induced Alzheimer’s Disease in Rats
Background: Alzheimer’s disease involves amyloid-β accumulation, oxidative stress, neuroinflammation, and cognitive decline. Scopolamine-induced Alzheimer’s disease mimics these pathological changes in experimental models. Diosmetin and Polmacoxib possess antioxidant, anti-inflammatory, and neuroprotective properties. This study evaluated their individual and combined effects on Scopolamine-induced behavioural and neurochemical impairments in rats. Aim: This study aimed to investigate the potential of Diosmetin and Polmacoxib to ameliorate scopolamine-induced cognitive deficits, oxidative stress, and cholinergic dysfunction in rats, thereby evaluating their efficacy as a therapeutic candidate for Alzheimer’s disease. Methods: Alzheimer’s disease was induced in rats by scopolamine (1 mg/kg, p.o. consecutively for 14 days). Pretreatment with Diosmetin, a flavonoid (100 and 200 mg/kg p.o.) and Polmacoxib, a COX-II-specific inhibitor (7 and 15 mg/kg, p.o.) and their combination were given for 14 days. Behavioural assessments (Y-maze, EPM, NORT and Morris water maze test) were performed on days 1st, 7th and 14th followed by biochemical parameters such as oxidative stress indices (CAT, GSH, SOD, and LPO), acetylcholinesterase level, proinflammatory cytokines (TNF-α and IL-1β), and β-amyloid expression, with histopathological evaluations of the hippocampus. Results: Scopolamine induced significant cognitive impairment, oxidative stress, neuroinflammation, and β-amyloid elevation in rats. Diosmetin and Polmacoxib improved learning and memory, restored antioxidant defences, reduced lipid peroxidation, and modulated AChE, inflammatory, and amyloidogenic markers. Histopathology confirmed neuronal preservation. Combination therapy produced superior neuroprotection compared with individual treatments, suggesting synergistic antioxidant, anti-inflammatory, anti-amyloidogenic, and neurotrophic effects. These findings support Diosmetin–Polmacoxib co-administration as a pote